Durable Symptom Improvement for Patients with Non-Transfusion Dependent Thalassemia Treated with Luspatercept: Patient-Reported Outcomes from the BEYOND Study
Khaled M. Musallam(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Kevin H.M. Kuo(University Health Network), Antonis Kattamis, Maria Domenica Cappellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), C. Pelligra, Alì Taher(American University of Beirut Medical Center), Jennifer Lord‐Bessen(Bristol-Myers Squibb (United States)), Loyse Felber Medlin(Bristol-Myers Squibb (Switzerland)), Mrudula B. Glassberg(Bristol-Myers Squibb (United States)), Shien Guo(Ithaka Harbors), Luciana Moro Bueno(Bristol-Myers Squibb (Switzerland))
Cited by 6
Related Papers
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study
|The Lancet|2011|1.3k
Thalassaemia
|The Lancet|2017|763
Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders
|Journal of Thrombosis and Haemostasis|2012|498
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel
|Haematologica|2014|389
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320